SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies SanegeneBio has entered into a significant global partnership with Genentech to develop RNAi therapeutics, receiving $200 million upfront and potential earnings up to $1.5 billion.

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies #United_States #Boston #Genentech #RNAi_Therapeutics #SanegeneBio

Alnylam Pharmaceuticals Joins Alliance to Enhance Genomic Research and Drive Precision Medicine Forward Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery to expand the genomic dataset that supports the development of precision medicine, enhancing drug discovery capabilities.

Alnylam Pharmaceuticals Joins Alliance to Enhance Genomic Research and Drive Precision Medicine Forward #United_States #San_Diego #Alnylam_Pharmaceuticals #Genomic_Discovery #RNAi_Therapeutics